Pureos Bioventures closes US$170m fundNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers. more ➔
Biotechs request money for COVID therapeut...German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies. more ➔
Polyneuron Pharmaceuticals AG extends Seri... Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments. more ➔
Mabion to licence COVID-19 jab from Vaxine...Polish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19 more ➔
4SC and Maruho end collaboration on Kv1.3...Japanese dermatology specialist Maruho Co. Ltd and drug discovery firm 4SC AG have terminated their development agreement related to 4SC’s blockers of Kv1.3 ion channels, which are required for maintenance … more ➔
MiNA Therapeutic bags £23m financingRNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates. more ➔
Vaccine developers unite to stand with sci...Nine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines. more ➔
Scope Fluidics gets EIB loan for infection...The European Investment Bank has lend up to €10m to Polish microbial diagnostics specialist Scope Fluidics AS. more ➔
COVID-19: Roche AG launches antigen rapid...Roche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea). more ➔
Unilever to replace fossil carbon in clean...Unilever has announced to invest €1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030. more ➔
